Drug intelligence / Profile preview

Lu-177-PP13D3

Development stage: Unknown
Lead developer: Molecular Targeting Technologies
Modality: Antibody-Radionuclide Conjugates → Antibody Conjugates → Antibody-Based Therapeutics, Peptides
Administration: Intravenous

Overview

Lu-177-PP13D3 is a targeted radiotherapeutic (TRT) being developed by Molecular Targeting Technologies (MTTI) for the treatment of neuroendocrine tumors (NETs). It consists of a peptide ligand, PP13D3, which specifically binds to the cholecystokinin-2 receptor (CCK2R), conjugated to the beta-emitting radioisotope Lutetium-177. CCK2R is frequently overexpressed in certain types of NETs, such as medullary thyroid carcinoma and gastroenteropancreatic neuroendocrine tumors. Upon binding and internalization, the Lutetium-177 delivers localized ionizing radiation, causing DNA damage and subsequent apoptosis in the target tumor cells while sparing surrounding healthy tissue. The drug is currently in Phase 1/2 clinical trials as a peptide receptor radionuclide therapy (PRRT).

Other names: Lutetium (177Lu) PP13D3

Targets

CCK2R (Cholecystokinin 2 Receptor)

Beyond the preview

Go deeper on Lu-177-PP13D3.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Lu-177-PP13D3.

Explore the full profile